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MOFs have demonstrated outstanding properties for the protection
and controlled release of different bio-entities, from proteins to
living cells. Carbohydrates, as pure molecules or as a component of
proteins and cells, perform essential biological functions. Thus, an
understanding of the role of carbohydrates in the formation
of MOF-based bio-composites will facilitate their application to
biotechnology and medicine. Here, we investigate the role of
carbohydrate molecular weight and chemical functionalization in
the formation of carbohydrate@MOF composites. We find that
chemical functionalization, such as carboxylation, that leads to an
enhancement of metal cation concentration at the surface of the
molecule triggers the rapid self-assembly of the MOF material,
zeolitic-imidazolate framework 8 (ZIF-8). Furthermore, we determine
the encapsulation efficiency and measure the release properties of
the carbohydrate under controlled conditions. Our findings show
that MOFs can be used to prepare a new class of biocomposites for
the delivery of carbohydrate-based therapeutics.
Introduction
Metal–organic frameworks (MOFs) are a class of crystalline
porous materials that typically possess high accessible surface
areas and narrow pore size distributions. In addition, the
chemical functionality, on their surface or within their pores,
can be precisely tuned.1 These unique properties have led to the
exploration of MOFs for application in areas such as catalysis, gas
storage, separation, microelectronics, and energy production.2–4 In
recent years, MOFs have been integrated with metallic, ceramic,
and biological moieties to form novel composite materials.5–8 In
the area of MOF bio-composites, it has been shown that MOFs can
be used as carriers for therapeutics ranging from small drugs9,10 to
large biomacromolecules.11,12 In the latter case, ZIF-8 has been
widely investigated.7,8 ZIF-8, and related polymorphs,11 can rapidly
form in the presence of different biomacromolecules.7 The
synthesis can be performed by adding the ZIF-8 building blocks,
2-methylimidazole (2mIM) and Zn2+, to proteins in the presence
of a co-precipitating agent (e.g. polyvinyl pyrrolidone) to assist
the protein encapsulation (a.k.a. the de novo approach).13,14
Alternatively, MOF formation can be triggered exclusively by
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Carbohydrate-based therapeutics are relevant drugs for the treatment of
cancer, diabetes, viral and bacterial infections. Therefore the efficient
encapsulation and controlled release of carbohydrates has great potential
in biomedicine. Here, we present a successful strategy to trigger the
spontaneous crystallization of metal–organic frameworks (MOFs) on
carbohydrates. The encapsulation of carbohydrates within ZIF-8 and
polymorphs (zinc-imidazolate-based MOFs) can be obtained in water.
The identification of conditions suitable for the successful preparation of
the composite were experimentally and computationally identified. By
controlling the chemical functionalization of the carbohydrate, the
formation of bio-composites can be obtained in seconds. A 100%
encapsulation efficiency was obtained. The controlled release of
carbohydrates from the MOF biocomposite was demonstrated. This
proof-of-concept study shows that a new generation of MOF bio-
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pure biomacromolecules.16 This method, termed biomimetic
mineralisation, has been successfully employed to encapsulate
proteins, DNA, enzymes, and antibodies and to coat viruses and
cells with MOFs.7,8,15–17 In these biocomposites the ZIF-8 shell
was shown to protect biomacromolecules from environments
that typically lead to their degradation, to act as a gate for
molecular transport, and to release the encapsulated bio-
molecules under controlled conditions.18,19 While progress has
been made toward understanding the biomimetic mineralisa-
tion process for certain biomacromolecules (e.g. proteins), for
others, e.g. carbohydrates (CHs), reliable preparation protocols
are not yet available (vide infra). Nevertheless, carbohydrate-
based molecules such as polysaccharides play crucial metabolic,
structural, physical, and functional roles in biological systems.20
The number of different biologically relevant polysaccharides
(also called glycans) that an organism produces (the glycome) is
estimated to be 10 to 104 times larger than the corresponding
number of proteins (the proteome).21 Because of the incremental
understanding of the biological role of glycans, their importance
in medicine is progressively increasing and carbohydrate-based
therapies have received considerable attention in recent years.21–23
Pure glycans can be delivered as effective therapeutics; for example
dextrin-2-sulphate was found to reduce replication of HIV-1 in
patients with AIDS and to induce a gradual regression of Kaposi’s
sarcoma lesions.24 The fusion of glycans with other biomacro-
molecules (glycosylation) can substantially modify the structure
and function of proteins and lipids influencing intermolecular
and intramolecular interactions; for instance, the type of glycan
present on IgG1 antibodies contributes to determining their
function, e.g. pro-inflammatory or anti-inflammatory properties.25
Glycans can be artificially attached to proteins (glycoengineering)26
to improve their robustness; the effectiveness of this method is
evidenced by the commercially available glycosylated proteins.27
Glycans are also active key players at the interface of viral capsids28
and cell membranes as CHs regulate adaptation, differentiation,
adhesion and signaling.22,29,30
Motivated by our interest in the exploitation of MOFs for
biotechnological applications and the widespread use of CHs in
biology,7,8 we investigated the biomimetic mineralisation of
ZIF-8 by CHs. A detailed understanding of how ZIF-8 encapsu-
lates mono- and poly-saccharides will expand the use of MOFs
in biotechnology and biomedicine.
A preliminary study that describes the facile encapsulation
of polysaccharides by ZIF-8 has been recently reported.31 In this
work, the synthesis was performed by adding polysaccharides
(e.g. dextran, molecular weight not disclosed) to a solution
of 2mIM; this solution mixture was then combined with a zinc
acetate solution. We have been unable to reproduce these
results in our laboratory, even after varying the reported proto-
col (e.g. order of reagents, temperature, and concentration).31
Thus, we considered the preparation of carbohydrates@MOF
composites an open scientific challenge and carried out a
systematic study to test CHs for the preparation of bio-MOF
composites. In this present study, we investigated the role of
mono-, di-, oligo-, and poly-saccharides as potential biomimetic
mineralisation agents for the formation of CHs@ZIF-8.
Here, we show that the encapsulation of CHs within ZIF-8 and
its structural polymorphs is not general. Indeed, the majority of the
CHs do not lead to the formation of MOF biocomposites. More
importantly, computational and experimental data show that the
chemical functionality of polysaccharides is critical to the repro-
ducible preparation of CHs@ZIF-8. Furthermore, to highlight the
potential application of biomimetic mineralisation to the release of
polysaccharide-based therapeutics, we used unlabelled and fluo-
rescein isothiocyanate-labelled carboxyl-functionalized polysac-
charides to study the encapsulation and release of CHs from
ZIF-8 composites. In summary, we have determined a general
method for preparing CHs@ZIF-8 biocomposites, which is an
important first step towards exploring these materials for the
release of polysaccharide-based therapeutics and for the con-
trolled growth of MOF shells around moieties of biological
interest, such as glycosylated proteins, viruses, and cells.
Results and discussions
Biomimetic mineralisation is a term that describes the triggered
formation of MOF particles or films by single biomacromole-
cules or more complex biological entities (e.g. a virus or cell).7 In
general, to ascertain whether the biomimetic mineralisation
process takes place, it is necessary to compare the particle
growth kinetics of water-based MOF precursor solutions with
and without the presence of the biomacromolecules. Biomimetic
mineralisation is confirmed when a difference in the formation
time for MOF particles is observed in the presence of the
biomacromolecules (e.g. faster production rate or larger amount
of particles). Typically, biomimetic mineralisation leads to the
formation of a MOF coating around the biomacromolecules that
engenders MOF-based bio-composites that possess novel
properties.7 We started our investigation into the preparation
of CHs@ZIF-8 composites by testing a variety of basic CH units
(i.e. monosaccharides) as potential biomimetic mineralisation
agents (Scheme 1), including neutral reducing monosaccharides
such as D-glucose (1), D-mannose (2), D-galactose (3), D-xylose (4);
a non reducing sugar such as methyl-b-D-glucopyranoside (5)
(Table S1, ESI†); reduced sugars such as D-glucitol (6) and
meglumine (7); and monosaccharides bearing a nitrogen such
as N-acetyl-D-glucosamine (8) and D-glucosamine (9).
Then, we tested water soluble oligosaccharides such as
sucrose (10), a typical disaccharide, D-gluconic acid-d-lactone (11),
the oxidized form of glucose, and maltodextrin (approximately
20 a-1,4-D-glucose units). Finally, we studied structural analogues
of the probed carbohydrates such as ethylene glycol (12) and
N-methyl-aminoethanol (13).
Initially, we followed the literature synthesis procedure that
reported the successful encapsulation of carbohydrates into
ZIF-8 and structural polymorphs. The specific CH was added
to an aqueous solution of 2-methylimidazole (2mIM, 160 mM) then
zinc acetate (40 mM in water) was added at ambient tempera-
ture to the CH/2mIM solution (Fig. S1, ESI†). To ascertain the
role of CHs in ZIF-8 formation, we employed varying quantities
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the solution (Table S2 and Fig. S2, ESI†). For the majority of the
sugars used, the purported biomimetic mineralisation effects
were negligible (Fig. S3–S15, ESI†). Only the amino functiona-
lized monosaccharides such as meglumine, and its analogous
N-methyl-aminoethanol (i.e. 7 and 13), showed a consistent
increase in turbidity with respect to the control solution (Fig. 1a).
To ascertain the formation of meglumine@ZIF-8 we fixed
the concentration of the ZIF-8 precursors while increasing the
concentration of the monosaccharide from 0.005 to 0.5 M. The
MOF particles prepared in the presence of meglumine were
collected by centrifugation, washed with water and ethanol,
then dried at ambient pressure and temperature. The powder
samples were investigated by X-ray diffraction (XRD) and FTIR.
From the XRD analysis a diamondoid topology, dia, was observed
for a meglumine concentration below 0.05 M; increasing the
concentration of meglumine to 0.125 M or above resulted
in ZIF-8 of sodalite topology, sod. This result suggests that
the framework topology depends on the concentration of
meglumine used during the synthesis (Fig. 1a(I)). After washing
with water and ethanol, we performed FTIR experiments on
samples prepared with different amounts of meglumine (Fig. 1a(II)).
Close inspection of the data revealed vibrational bands typical
of Zn(2mIM)2 networks: 3120 and 2926 cm
1 (C–H stretching of
the methyl imidazole),32 1420 cm1 (ring stretching of methyl
imidazole),32 900–1350 (in plane bending of imidazole ring),33,34
600–800 cm1 (out of plane bending of imidazole ring),
421 cm1 (Zn–N stretching).33 However, we could not detect
any infrared absorption band related to meglumine. Thus,
despite our observation that the monosaccharide was acting as
an initiator for MOF formation, the final crystalline material was
found to be a single phase of Zn-imidazolate framework of dia or
sod topology (Fig. 1b). It is worth highlighting that our SAXS
investigation of the formation of ZIF-8 with a 0.5 M meglumine
concentration did not reveal the presence of a crystalline
material; however, a pattern consistent with sod was found
after washing with ethanol. We monitored the transformation
between the amorphous phase into sod (Fig. 1c). Despite
the origin of the phase transformation remaining unclear, the
importance of the washing procedure is demonstrated. For this
reason, in this manuscript, the washing procedure used for the
different sets of samples is specified.
The XRD and FTIR data lead us to conclude that meglumine,
and the analogous N-methyl-aminoethanol, triggers the formation
of MOF due to the presence of basic amino groups. Indeed, the
addition of a base (e.g. triethanol amine) to MOF precursor
solutions is an established method for the deprotonation of
ligands and rapid crystallization of MOFs.35,36 Controlling the
local formation of base with light (i.e. photobase generator), MOF
growth was enabled in specific locations;37 this demonstrates
that different kinetics of the MOF formation are induced by an
exogenous base. To prove this hypothesis, we measured the
pH of the precursor solution of the MOF in the presence of
an increasing amount of meglumine. We ascertained that
Scheme 1 Use of carbohydrates (CHs) with 2-methylimidazole (2mIM)
and Zn(OAc)2 to trigger the biomimetic mineralisation and the subsequent
formation of carbohydrates encapsulated in ZIF-8 (CHs@ZIF-8).
Fig. 1 (a) Photograph of a control sample (2mIM, Zn(OAc)2, and water) and the same solution in the presence of meglumine, diffraction patterns, and
infrared spectra of the Zn(2mIM)2 produced using different concentrations of meglumine. A topology dependence on the amount of this mono-
saccharide was observed. (b) Schematic that illustrates meglumine as a crystallization agent. (c) SAXS kinetics that shows the phase transition from
amorphous Zn(2mIM)2 to sodalite triggered by the presence of ethanol. The formation of sodalite was detected by the presence of the three peaks
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the pH of the solution was in the 12–14 range (Table S3, ESI†),
thus confirming the basicity of meglumine. Under specific
conditions, other monosaccharides (e.g. D-glucose, methyl-a-D-
glucopyranoside, D-glucitol, D-gluconic acid d-lactone, D-glucos-
amine hydrochloride, N-acetyl-D-glucosamine, and D-xylose)
appeared (visual inspection) to promote biomimetic mineralisa-
tion; we believe that they influence the ligand deprotonation (see
details in Table S3, ESI†). To understand the effect that the
preparation methods have, we studied different mixing procedures
and reaction temperatures for methyl-a-D-glucopyranoside (5),
glucitol (6), and meglumine (7) (Fig. S16–S18, ESI†). While
meglumine induced a cloudy solution, inducing solution turbidity
with the other CHs required elevated reaction temperature and/or
sonication. More importantly, for the entire set of small CHs
tested, FTIR analysis carried out on the solid powders after
washing (H2O and EtOH) did not provide any evidence for
the encapsulation of CHs within zinc-imidazolate-based MOFs
(Fig. S19–S22, ESI†).
Given these data we turned our attention to the role of the
CH molecular weight in the formation of CHs@MOFs. We
selected a series of dextrans of different molecular weights
(i.e. 6, 40, and 70 kDa) as potential biomimetic mineralisation
agents. Close visual inspection of these reactions gave no
indication of rapid MOF formation (Table S4, ESI†). To assess
these reactions more quantitatively, we performed a kinetic
assessment of particle formation for 40 and 70 kDa dextran
using UV-Vis spectroscopy. The solution transmittance was
probed with an incident wavelength of 595 nm (Fig. S23, ESI†).
No change in transmittance was observed over a time period of
30 min for either dextran. Furthermore, the change in trans-
mittance of the negative control solution (i.e. a solution without
the biomacromolecules) did not differ significantly from the
ones containing the dextran molecules. As a positive control,
bovine serum albumin (BSA) was used as the biomacromole-
cule; in this case, a decrease in the transmitted radiation was
measured due to the formation of BSA@MOF particles. Combined,
these experiments provide evidence that dextrans, regardless of
molecular weight, do not induce the rapid formation of MOF-
based biocomposites. To assess if the molecular structure of
the polymer could play a role in the formation of a composite,
we tested maltodextrin and dextran (Fig. S24, ESI†). Again, no
evidence of biomimetic mineralisation was detected. Finally,
we investigated solid-state CHs (cellulose) to ascertain if the
surface could trigger the formation of ZIF-8. As a control, we
used a glass slide. From our SEM images and FTIR investiga-
tions at 30 s and 30 min, both substrates were ineffective for
inducing the growth of ZIF-8 or its polymorphs; however,
within 24 hours some particles can be observed on both glass
and cellulose (Fig. S25–S32, ESI†). Despite the different compo-
sitions tested and synthetic conditions used, we could not
reproduce the result previously reported by Liang et al.31 Thus,
we considered that the challenge of preparing CH@MOFs using
a general procedure was unresolved.
Recently, we explored the role of protein surface charge
on the biomimetic mineralization of ZIF-8.38 By modifying
the protein surface charge via succinylation or amination, we
demonstrated that it is possible to trigger or prevent the
biomimetic mineralization on several enzymes.38 Inspired by
this work, we were motivated to establish whether the chemical
functionalization of CHs could produce biomimetic mineraliza-
tion agents for the preparation of CHs@ZIF-8. Thus, we used
commercially available amino- and carboxylate-functionalized
dextrans with similar molecular weight (10 kDa and 10–20 kDa,
respectively). A 1 : 4 metal-to-ligand ratio was set for consistency
with prior experiments. While the amino-functionalized CH did
not show evidence of biomimetic mineralisation, the solution
containing the dextran with COO functionality (CM-dextran)
showed a rapid transition from transparent to opalescent
(Fig. 2a and Fig. S33 and related video ESI†). To study the
influence of the CM-dextran on the pH, the concentration of
the CH was varied in the 0–1.44 mg mL1 range (Fig. S34, ESI†).
In presence of the ligand, a ca. 3% maximum variation was
measured, thus the role of the pH in the formation of the MOF
was considered to be negligible.
The powder from the vial was collected via centrifugation
and washed with water and ethanol (details in ESI†). The dried,
powder was then analyzed by FTIR spectroscopy. Characteristic
modes of carboxymethyl dextran (CM-dextran) were observed at
approximately 1608 cm1 that can be attributed to the COO
stretching vibration of CM-dextran,38,39 and at 2850–3600 cm1
stretching vibrations of the OH group were observed40 (a more
comprehensive interpretation of the FTIR spectra is available in
Fig. S35 ESI†). This data supports the formation of a MOF
biocomposite based on CM-dextran and Zn(2mIM)2.
To understand the impact of functional group substitution
on the likelihood of dextran carbohydrates to seed ZIF-8
formation, we modelled the electrostatic potential and ion
concentrations near charged dextrans as a function of their
degree of substitution (DS) and the type of chain functionality.
Fig. 2 (a) Schematic of the biomimetic mineralisation of CM-dextran@
Zn(2mIM)2 according to the infrared investigation; photograph of a control
sample (2mIM, Zn(OAc)2 and water) and the same solution in presence
of CM-dextran. (b) Schematic of the ion-permeable sphere model of a
carbohydrate molecule of radius Rg used to calculate the electrostatic
potential and ion concentrations near the molecule (R c Rg is the radius
where the potential is assumed to approach zero). (c) Calculated electro-
static potential at the center of the carbohydrate versus degree of
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Since most of the pervaded volume occupied by a dextran
molecule is expected to be accessible to the ions in solution,
we modelled the effect of adding positive charges (for amine
functionalization, AM) or negative charges (for carboxymethyl
functionalization, CM) to a neutral dextran backbone by calcu-
lating the electrostatic potential and electrolyte concentration
surrounding an ion-permeable sphere (Fig. 2b) using the
Poisson–Boltzmann (PB) equation (details in Fig. S36–S38,
ESI†).41 Fig. 2c shows the electrostatic potential and zinc ion
concentration enhancement at the center of the ion-permeable
sphere calculated as a function of DS. In this plot, the AM
functionalization depletes zinc ions near dextran, while the CM
functionalization enhances the Zn2+ concentration in and
around the biomacromolecule. In particular, at the approxi-
mate DS value of the CM-dextran, the zinc ion enhancement is
around 10, which was found to lead to ZIF-8 formation around
various proteins.42 Thus both the computational modelling and
experimental results confirm the relevance of CH charge on the
biomimetic mineralisation of Zn(2mIM)2 MOFs. As an additional
support to the role of the functionalization, COO functional
groups where used to facilitate the formation of ZIF-8 on polymers
and graphene.43,44
Having identified a CH that can be used as a reliable
biomimetic mineralisation agent, we turned our attention to
understanding the effect of varying the Zn2+ : 2mIM ratio.
Indeed, in a previous study,11 we noted that the choice
of Zn2+ : 2mIM ratio affords the encapsulation of BSA within
networks of different topologies, including amorphous, sod-,
dia-Zn(2mIM)2 and unknown phases (U12, U13, and U14).
11
Furthermore, it was experimentally demonstrated that the final
topology of the composite can depend on the specific type of
biomacromolecule used.11 For the study of this CH@ZIF-8,
we prepared solutions using 1 : 2.52 (A), 1 : 3.47 (B), 1 : 4 (C),
1 : 6 (D), 1 : 8 (E), and 1 : 16 (F) Zn2+ : 2mIM ratios using a fixed
concentration of CM-dextran (0.36 mg mL1). After a reaction
time of 24 h, the samples were investigated by XRD (Fig. 3a).
For the sample with the lowest Zn2+ : 2mIM ratio, the powdery
material was found to be a mixture of phases dominated by
U1211 and sodalite. The biomineralised powders with 1 : 3.47
and 1 : 4 ratios were predominantly sodalite topology. A further
increase of the ligand concentration (1 : 6) produced a pure
diamond network that turned into pure sodalite for the highest
ratio (1 : 16). The SEM images in Fig. 3b show that globular
particles of ca. 8 mm with rough surfaces were obtained for the
lowest metal/ligand ratio (1 : 2.52). Clusters of smaller particles
were observed for 1 : 3.47 and 1 : 4 ratios (ca. 25 and 20 nm,
respectively, Fig. S40–S41, ESI†). For the 1 : 6 ratio a lamellar
morphology typically associated with dia-Zn(2mIM)2 was
observed, with a broad size distribution between 1 and 5 mm.
This morphology was partially maintained for the 1 : 8 ratio,
Fig. 3 (a) XRD, (b) SEM, and (c) FTIR of the CM-dextran@ZIF-8 biocomposites obtained with different metal-to-ligand ratios (A = 1 : 2.52, B = 1 : 3.47,
C = 1 : 4, D = 1 : 6, E = 1 : 8, F = 1 : 16). SEM scale bar = 2 mm. (d) Encapsulation efficiency of the six systems using FITC-CM-dextran with different
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while for 1 : 16 typical rhombic dodecahedron particles of
ca. 2.5 mm were noted.
After washing the powders with water and ethanol (proce-
dure optimized for the removal of the CM-dextran adsorbed on
the surface of ZIF-8 crystals, S42, ESI†), samples were investi-
gated using FTIR spectroscopy (Fig. 3c). The vibrational mode
at 421 cm1, found in all samples, is assigned to the Zn–N
stretching mode and thus confirms the networks are composed
of 2mIM connected via Zn nodes.33 Additionally, both the
COO mode at 1608 cm1 and the large OH band in the region
3600–2850 cm1 indicate that CM-dextran is encapsulated.
Based on the intensity of the modes engendered by CH, the
amount of encapsulated CH was found to depend on the metal-
to-ligand ratio. For example, a higher loading of CM-dextran
was measured in the sample prepared using Zn2+ : 2mIM =
1 : 3.47. In general, drug loading, also called encapsulation
efficiency (EE), is an important parameter in drug delivery as
it pertains to the amount of therapeutic within the carrier.8 As
CH-based therapeutics can be expensive and difficult to
prepare,45,46 we decided to run a quantitative assessment using
a commercially fluorescein isothiocyanate-tagged CM-dextran,
here named FITC-CM-dextran. Indeed, the use of FITC allows to
use a UV-Vis spectrometer to study the release of the carbohydrate
from the composite. The synthesis of the FITC-CM-dextran@ZIF-8
biocomposites was undertaken using all the previously tested
Zn2+ : 2mIM ratios: 1 : 2.52, 1 : 3.47, 1 : 4, 1 : 6, 1 : 8, and 1 : 16 (here
named samples AF, BF, CF, DF, EF, and FF, respectively). Then,
we analysed the reaction supernatant using UV-Vis spectroscopy
to quantitatively measure encapsulation efficiency (EE = 100%)
at 1 : 3.47 (Fig. 3d). A progressive decrease in the encapsulated
amount of FITC-CM-dextran with increasing concentration of
2mIM was measured. We believe that the progressive decrease in
the encapsulation efficiency could be attributed to a competition
between heterogeneous (biomolecule-mediated growth) and
homogenous nucleation (facilitated by an increased metal-to-
ligand ratio); however, further studies are needed to validate
this hypothesis.
Based on parameters including a high EE and low amounts
of 2mIM, we decided that the best procedure to synthesize
CM-dextran@ZIF-8 (sod), was to employ Zn2+ : 2mIM = 1 : 3.47.
Using this ratio of MOF precursors we further optimized the
reaction conditions by varying the CH concentration. Thus
we prepared new samples named B1, B2, B3, and B4 with
0.18, 0.36, 0.72, and 1.44 mg mL1 of CM-dextran solutions,
respectively. Photos were taken during the reaction to record
visual evidence of biomimetic mineralisation. Simultaneously,
a control sample (C, Fig. 4a), with Zn2+ : 2mIM = 1 : 3.47 pre-
pared using the same conditions, excluding CH, was monitored
to evaluate the biomimetic mineralisation effect induced by the
different concentrations of CM-dextran. Fig. 4a shows photos
taken after a reaction time of 2 seconds; all sample solutions
(B1, B2, B3, and B4) rapidly turned opalescent confirming that
the biomimetic mineralisation occurs.
Increasing the concentration of CM-dextran exceeding
3.24 mg mL1 did not lead to appreciable biomimetic miner-
alisation; we hypothesize that this could be due to the excess of
COO removing Zn2+ cations from the MOF crystallization
process.47 After 24 h, the powders were centrifuged from each
of the solutions and washed. We noted that different amounts
of solid material were produced for each of the conditions
(Table S5, ESI†). After washing, the powders were studied by
FTIR (spectra reported in Fig. S43 ESI†). For all samples,
vibrational modes attributed to the CH (e.g. OH band in the
3650–2850 cm1) and Zn(2mIM)2 (e.g. Zn–N stretching mode
at 421 cm1) were observed. This indicates that CM-dextran
gave rise to CM-dextran@ZIF-8 biocomposites for each of
the concentrations. To ascertain the crystallinity of the solid
material, XRD analysis was conducted on samples before and
after ethanol washing. For the entire set of samples (B1–4) washed
only with water, sodalite was the dominant phase obtained
(Fig. 4b). This demonstrates the high selectivity of this recipe
for the preparation of CM-dextran@ZIF-8.
SEM images revealed the presence of particles with average
particles size below 200 nm (Fig. 4c). Although we could not
find specific information on the influence the size of ZIF-8 for
in vivo drug delivery, for other particles, this size has been
identified as a critical value; indeed, nanocarriers larger than
200 nm have been shown to accumulate in the liver and spleen.48
To study the EE as a function of the CH concentration, FITC-
CM-dextran was used as a biomimetic mineralisation agent
for the preparation of a set of biocomposites equivalent
to the previously prepared set B. The samples prepared with
FITC-CM-dextran were named set BF (i.e. BF1, BF2, BF3, BF4).
The powders were investigated via SEM; surprisingly larger particles
were formed (Fig. S44, ESI†). The confocal microscope (CLSM)
Fig. 4 (a) Photos of samples with metal/ligand ratio 1 : 3.47 and sugar
concentrations of B1 = 0.18, B2 = 0.36, B3 = 0.72, and B4 = 1.44 mg mL1
against control C without sugar. (b) Powder XRD of the same system.
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confirms the different particle size (Fig. 5a–d); this variation
from CM-dextran was attributed to the chemical modification
of the polysaccharide.
The homogenous luminescence across the particles confirm
the even distribution of the FITC-CM-dextran within the ZIF-8
particles. A PXRD analysis confirms the dominant sod topology
for all the BF samples (Fig. 5e).
Considering the relevance of the EE in the delivery of
biotherapeutics,49 we determined the amount of FITC-CM-
dextran encapsulated in ZIF-8. The assessment was performed
using UV-Vis and the Lambert–Beer law with an experimental
calibration of different concentrations of FITC-CM-dextran (see
ESI†). As shown in Fig. 5f, the measured EE was influenced
by the concentrations of the FITC-CM-dextran used as the
biomimetic mineralisation agent. Intermediate concentrations
of FITC-CM-dextran lead to higher EE: ca. 100% of the FITC-
CM-dextran was encapsulated in case of BF2. For the lowest and
the higher concentrations of biomacromolecules, the EE dropped
to ca. 40% (sample BF4). We then turned our efforts to CH release.
Due to the density of COO in the CH and the affinity for Zn2+
cations, we decided to investigate the amount of model drug
available as a therapeutic that could be re-dissolved into its
original molecular form. The dissolution process was performed
leaving the biocomposites in presence of EDTA for 1 h (ESI†) at
room temperature. In all cases, after etching the particles, a visual
inspection revealed transparent solutions without a detectable
amount of precipitate. Using UV-Vis, we calculated the percentage
of FITC-CM-dextran from the correspondent CH@ZIF-8 (Fig. 5g).
Again, BF2 showed the best performance as 100% of the loaded
CH was available in solution after the release. For all the other
samples, a percentage of the FITC-CM-dextran ranging from 25 to
51% was not available as a molecule in solution because of the
combined losses during the encapsulation and release processes.
We hypothesize that, during the dissolution of CH@ZIF-8,
because of the strong affinity of carboxy-methyl functional groups
with cations,50 FITC-CM-dextran could coordinate Zn2+ to form
insoluble products. Because of the ideal release performance of
BF2, this sample was tested to investigate the controlled release
profiles, which is another important property for drug release
systems.51 We used 3 different concentrations of EDTA (i.e. 10,
20 and 40 mM), and measured the release profile.
In Fig. 5h–j, the experimental data were fitted with a logistic
fitting function that can be used in systems in which the
dissolution of the carrier is involved.52 In particular, this model
is appropriate for ZIF-8 as it is used for hydrophobic carriers.53–55
For the 10 mM EDTA solution, roughly 15 min were required to
release 50% of the model drug; the remaining ca. 50% was
released within 40 min. Using the 20 mM EDTA solution, in
10 min ca. 50% of the FITC-CM-dextran was released, while
ca. 100% release was measured in 30 min. A further increase of
the EDTA concentration (40 mM) afforded the release of 50% of
the model CH in ca. 7 min; in 16 min a ca. 100% was released.
These values prove that the release profile depends on the
EDTA concentration, thus we demonstrated that a controlled
release of CH encapsulated into ZIF-8 is possible. To ascertain
the release properties using a different medium, a 100 mM
sodium citrate solution (pH = 6) was tested and the release of
FITC-CM-dextran from the MOF biocomposite was successfully
measured (S45, ESI†).
In conclusion, we have shown that a large number of CHs
do not work as biomimetic mineralisation agents. However,
CHs decorated with COO functional groups can be employed
reproducibly for the encapsulation of carbohydrates in MOFs
(CH@MOFs). From our simulations this is can be attributed
to a coulombic attraction between the functional groups and
Zn2+ cations. By assessing synthesis conditions using different
Zn2+: 2mIM ratios and concentrations of carboxymethyl-dextran
(CM-dextran) as the biomimetic mineralisation agent, we optimized
a system that can form CH@ZIF-8 directly in water. We used a
fluorescein isothiocyanate (FITC) tagged CM-dextran (FITC-CM-
dextran) and determined conditions for the 100% encapsula-
tion and 100% release of the model carbohydrate therapeutic.
Fig. 5 (a–d) Confocal microscopy images of sample B obtained using metal-to-ligand ratio 1 : 3.47 and FITC-CM-dextran at various concentrations
(BF1 = 0.18, BF2 = 0.36, BF3 = 0.72, BF4 = 1.44 mg mL1). (e) Powder XRD of the same system. (f) Encapsulation efficiency for each system (values are
averages of 3 tests). (g) Overall release of the FITC-CM-dextran with respect to the original concentration used for the biomimetic mineralisation (values
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Lastly, by varying the amount of EDTA, different release profiles
were measured, showing a direct dependence between the
concentration of the chelating agent and the release rate. As
CHs play a number of relevant biological roles, we believe that
this discovery will pave the way for the preparation of a new
class of MOF-biocomposites for the delivery of carbohydrate-
based biotherapeutics and for the choice of the specific CHs
involved in glyco-engineering processes.
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26 R. J. Solá and K. Griebenow, J. Pharm. Sci., 2009, 98,
1223–1245.
27 L. Zhang, S. Luo and B. Zhang, mAbs, 2016, 8, 205–215.
28 A. Chandrasekaran, A. Srinivasan, R. Raman, K. Viswanathan,
S. Raguram, T. M. Tumpey, V. Sasisekharan and
R. Sasisekharan, Nat. Biotechnol., 2008, 26, 107–113.
29 K. W. Moremen, A. Ramiah, M. Stuart, J. Steel, L. Meng,
F. Forouhar, H. A. Moniz, G. Gahlay, Z. Gao, D. Chapla,



































































































This journal is©The Royal Society of Chemistry 2019 Mater. Horiz., 2019, 6, 969--977 | 977
Rosa, C. Geisler, A. V. Nairn, J. Seetharaman, S.-C. Wu,
L. Tong, H. J. Gilbert, J. LaBaer and D. L. Jarvis, Nat. Chem.
Biol., 2017, 14, 156–162.
30 A. O. Tzianabos, Clin. Microbiol. Rev., 2000, 13, 523–533.
31 K. Liang, R. Wang, M. Boutter, C. M. Doherty, X. Mulet and
J. J. Richardson, Chem. Commun., 2017, 53, 1249–1252.
32 Y. Hu, H. Kazemian, S. Rohani, Y. Huang and Y. Song,
Chem. Commun., 2011, 47, 12694.
33 Z.-X. Low, J. Yao, Q. Liu, M. He, Z. Wang, A. K. Suresh,
J. Bellare and H. Wang, Cryst. Growth Des., 2014, 14, 6589–6598.
34 M. Jian, B. Liu, R. Liu, J. Qu, H. Wang and X. Zhang, RSC
Adv., 2015, 5, 48433–48441.
35 L. Huang, Microporous Mesoporous Mater., 2003, 58, 105–114.
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